Bexion Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Established: 2006-01-01

Employees: 11

Market Cap: -

Website: http://www.bexionpharma.com

Clinical Trials

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Phase 1

Active, not recruiting

Conditions: Metastatic Colorectal Carcinoma
Neuropathy

Interventions: Drug: BXQ-350
Other: Placebo

First Posted Date: 2022-04-12

Last Posted Date: 2024-12-20

Lead Sponsor: Bexion Pharmaceuticals, Inc.

Target Recruit Count: 195

Registration Number: NCT05322590

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸
Pacific Hematology Oncology Associates, San Francisco, California, United States

and more 9 locations

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

Early Phase 1

Active, not recruiting

Conditions: Neuropathy;Peripheral
Chemotherapy-induced Peripheral Neuropathy

Interventions: Drug: BXQ-350
Other: Placebo

First Posted Date: 2022-03-22

Last Posted Date: 2024-12-19

Lead Sponsor: Bexion Pharmaceuticals, Inc.

Target Recruit Count: 21

Registration Number: NCT05291286

Locations: 🇺🇸
The Ohio State Unviersity, Columbus, Ohio, United States
🇺🇸
CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)

Phase 1

Terminated

Conditions: Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant

Interventions: Drug: BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations

First Posted Date: 2021-02-25

Last Posted Date: 2024-12-20

Lead Sponsor: Bexion Pharmaceuticals, Inc.

Target Recruit Count: 10

Registration Number: NCT04771897

Locations: 🇺🇸
Nationwide Children's, Columbus, Ohio, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Continued Treatment for Participants Enrolled in Studies of BXQ-350

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: BXQ-350

First Posted Date: 2020-05-27

Last Posted Date: 2024-12-20

Lead Sponsor: Bexion Pharmaceuticals, Inc.

Target Recruit Count: 5

Registration Number: NCT04404569

Locations: 🇺🇸
University of Cincinnati Barrett Center, Cincinnati, Ohio, United States
🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: BXQ-350

First Posted Date: 2019-05-30

Last Posted Date: 2021-07-22

Lead Sponsor: Bexion Pharmaceuticals, Inc.

Target Recruit Count: 9

Registration Number: NCT03967093

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Nationwide Children's, Columbus, Ohio, United States

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BXQ-350

First Posted Date: 2016-08-09

Last Posted Date: 2021-07-22

Lead Sponsor: Bexion Pharmaceuticals, Inc.

Target Recruit Count: 86

Registration Number: NCT02859857

Locations: 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

and more 1 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy